1887
Volume 2013, Issue 4
  • ISSN: 2305-7823
  • E-ISSN:

Abstract

Venous thromboembolism is associated with a high morbidity and, if left untreated, may progress to fatal outcome. The standard treatment of venous thromboembolism consists of heparin followed by long-term treatment with a vitamin K antagonist. However, the use of vitamin K antagonist has several inherent problems and practical challenges. These challenges have prompted the search for new oral anticoagulant drugs including direct factor Xa inhibitors (e.g., rivaroxaban, apixaban and edoxaban) and thrombin inhibitors (e.g., dabigatran). To date, results for dabigatran, rivaroxaban, apixaban, for the treatment of VTE have been published. Recently, results of the 4th new oral anticoagulant agent, edoxaban, have been published in the Hokusai-VTE study. This review discusses the Hokusai-VTE study with special emphasis on its salient features (compared to other new oral anticoagulant studies) in addition to an overview on some key lessons learnt.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2013.50
2014-01-01
2019-08-20
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2013/4/gcsp.2013.50.html?itemId=/content/journals/10.5339/gcsp.2013.50&mimeType=html&fmt=ahah

References

  1. [1]. Anderson   FA Jr., , Wheeler   HB. . Physician practices in the management of venous thromboembolism: a community-wide survey. . J Vasc Surg . 1992; ;16: : 707– 771 .
    [Google Scholar]
  2. [2]. Heit   JA. . Venous thromboembolism epidemiology: implications for prevention and management. . Semin Thromb Hemost . 2002; ;   s2 : 3– 14 .
    [Google Scholar]
  3. [3]. Prandoni   P., , Noventa   F., , Ghirarduzzi   A., , Pengo   V., , Bernardi   E., , Pesavento   R., , Iotti   M., , Tormene   D., , Simioni   P., , Pagnan   A. . The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. . Haematologica . 2007; ;92: : 199– 205 .
    [Google Scholar]
  4. [4]. Schulman   S., , Beyth   RJ., , Kearon   C., , Levine   MN. . Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). . Chest . 2008; ;133: : 257S– 298S .
    [Google Scholar]
  5. [5]. Hull   RD., , Raskob   GE., , Hirsh   J., , Jay   RM., , Leclerc   JR., , Geerts   WH., , Rosenbloom   D., , Sackett   DL., , Anderson   C., , Harrison   L., , Gent   M. . Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. . N Engl J Med . 1986; ;315: 18 : 1109– 1114 .
    [Google Scholar]
  6. [6]. Franchini   M., , Mannucci   M. . New anticoagulants for treatment of venous thromboembolism. . Eur J Intern Med . 2012; ;23: : 692– 695 .
    [Google Scholar]
  7. [7]. Schulman   S., , Kearon   C., , Kakkar   AK., , Mismetti   P., , Schellong   S., , Eriksson   H., , Baanstra   D., , Schnee   J., , Goldhaber   SZ., , RE-COVER Study Group. . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. . N Engl J Med . 2009; ;361: : 2342– 2352 .
    [Google Scholar]
  8. [8]. EINSTEIN Investigators., , Bauersachs   R., , Berkowitz   SD., , Brenner   B., , Buller   HR., , Decousus   H., , Gallus   AS., , Lensing   AW., , Misselwitz   F., , Prins   MH., , Raskob   GE., , Segers   A., , Verhamme   P., , Wells   P., , Agnelli   G., , Bounameaux   H., , Cohen   A., , Davidson   BL., , Piovella   F., , Schellong   S. . Oral rivaroxaban for symptomatic venous thromboembolism. . N Engl J . 2010; ;363: : 2499– 2510 .
    [Google Scholar]
  9. [9]. EINSTEIN-PE Investigators., , Büller   HR., , Prins   MH., , Lensin   AW., , Decousus   H., , Jacobson   BF., , Minar   E., , Chlumsky   J., , Verhamme   P., , Wells   P., , Agnelli   G., , Cohen   A., , Berkowitz   SD., , Bounameaux   H., , Davidson   BL., , Misselwitz   F., , Gallus   AS., , Raskob   GE., , Schellong   S., , Segers   A. . Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. . N Engl J Med . 2012; ;366: : 1287– 1297 .
    [Google Scholar]
  10. [10]. Agnelli   G., , Buller   HR., , Cohen   A., , Curto   M., , Gallus   AS., , Johnson   M., , Masiukiewicz   U., , Pak   R., , Thompson   J., , Raskob   GE., , Weitz   JI., , AMPLIFY Investigators. . Oral apixaban for the treatment of acute venous thromboembolism. . N Engl J Med . 2013; ;369: : 799– 808 .
    [Google Scholar]
  11. [11]. Camm   AJ., , Bounameaux   H. . Edoxaban. A new oral direct factor Xa inhibitor. . Drugs . 2011; ;71: : 1503– 1526 .
    [Google Scholar]
  12. [12]. Gonsalves   WI., , Pruthi   RK., , Patnaik   MM. . The new oral anticoagulants in clinical practice. . Mayo Clin Proc . 2013; ;88: 5 : 495– 511 .
    [Google Scholar]
  13. [13]. Hokusai-VTE Investigators., , Büller   HR., , Décousus   H., , Grosso   MA., , Mercuri   M., , Middeldorp   S., , Prins   MH., , Raskob   GE., , Schellong   SM., , Schwocho   L., , Segers   A., , Shi   M., , Verhamme   P., , Wells   P. . Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. . N Engl J Med . 2013; ;369: : 1406– 1415 .
    [Google Scholar]
  14. [14]. Guyatt   GH., , Akl   EA., , Crowther   M., , Gutterman   DD., , Schuünemann   HJ., , American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. . Executive Summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. . Chest . 2012; ;141: 2 suppl : 7S– 47S .
    [Google Scholar]
  15. [15]. Goldhaber   SZ., , Visani   L., , De Rosa   M. . Acute pulmonary embolism: clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER). . Lancet . 1999; ;353: : 1386– 1389 .
    [Google Scholar]
  16. [16]. Murin   S., , Romano   PS., , White   RH. . Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. . Thromb Haemost . 2002; ;88: : 407– 414 .
    [Google Scholar]
  17. [17]. Kearon   C. . Natural history of venous thromboembolism. . Circulation . 2003; ;107: : I22– I30 .
    [Google Scholar]
  18. [18]. Deitelzweig   SB., , Lin   J., , Kreilick   C., , Hussein   M., , Battleman   D. . Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. . Adv Ther . 2010; ;27: : 623– 633 .
    [Google Scholar]
  19. [19]. Willey   VJ., , Bullano   MF., , Hauch   O., , Reynolds   M., , Wygant   G., , Hoffman   L., , Mayzell   G., , Spyropoulos   AC. . Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. . Clin Ther . 2004; ;26: : 1149– 1159 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2013.50
Loading
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error